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Summary
Background Malaria in pregnancy is associated with maternal and fetal morbidity and mortality. In 2006, WHO 
recommended use of artemisinin-based combination treatments during the second or third trimesters, but data on 
eﬃ   cacy and safety in Africa were scarce. We aimed to assess whether artemether–lumefantrine was at least as 
eﬃ   cacious as oral quinine for the treatment of uncomplicated falciparum malaria during the second and third 
trimesters of pregnancy in Mbarara, Uganda.
Methods We did an open-label, randomised, non-inferiority trial between October, 2006, and May, 2009, at the 
antenatal clinics of the Mbarara University of Science and Technology Hospital in Uganda. Pregnant women were 
randomly assigned (1:1) by computer generated sequence to receive either quinine hydrochloride or artemether–
lumefantrine, and were followed up weekly until delivery. Our primary endpoint was cure rate at day 42, conﬁ  rmed by 
PCR. The non-inferiority margin was a diﬀ  erence in cure rate of 5%. Analysis of eﬃ   cacy was for all randomised 
patients without study deviations that could have aﬀ  ected the eﬃ   cacy outcome. This study was registered with 
ClinicalTrials.gov, number NCT00495508.
Findings 304 women were randomly assigned, 152 to each treatment group. By day 42, 16 patients were lost to follow-
up and 25 were excluded from the analysis. At day 42, 137 (99·3%) of 138 patients taking artemether–lumefantrine 
and 122 (97·6%) of 125 taking quinine were cured—diﬀ  erence 1·7% (lower limit of 95% CI –0·9). There were 
290 adverse events in the quinine group and 141 in the artemether–lumefantrine group. 
Interpretation Artemisinin derivatives are not inferior to oral quinine for the treatment of uncomplicated malaria in 
pregnancy and might be preferable on the basis of safety and eﬃ   cacy.
Funding Médecins Sans Frontières and the European Commission.
Introduction
40% of all women are estimated to be exposed to malaria 
infection during the course of pregnancy;
1 substantial 
proportions of maternal mortality have been attributed to 
malaria in Sudan (37·2%)
2 and Zimbabwe (24%).
3 Each 
year an estimated 75  000–200  000 deaths of infants are 
associated with malaria infection in pregnancy.
4 In highly 
endemic areas, infection is often asymptomatic and can 
remain undetected while causing placental malaria and 
severe maternal anaemia.
4,5
Adverse consequences for the fetus and neonate 
attributable to maternal malaria infection include low 
birthweight due to prematurity or intrauterine growth 
retardation, fetal parasite exposure, and congenital 
infection. Infant mortality is linked to prematurity and 
low birthweight.
6 Maternal anaemia at delivery is strongly 
related to low haemoglobin concentrations throughout 
infancy, irrespective of birthweight, and in some settings 
an important contributor to infant morbidity.
7
Chloroquine and sulfadoxine–pyrimethamine are not 
recommended for the treatment of malaria in pregnancy 
because of widespread resistance.
8 Although quinine is 
deemed to be safe in pregnancy,
9,10 the three-times daily 
7-day regimen is not ideal because of many adverse 
eﬀ  ects that lead to poor compliance.
11 Few trials have 
investigated the eﬃ   cacy of quinine treatment in Africa 
during pregnancy. In 2002, the ﬁ  ndings of a study in 
Sudan
12 showed reassuring quinine eﬃ   cacy.  WHO 
recommends artemisinin combination therapies (ACTs) 
in the second and third trimester, in agreement with 
recommendations in patients that are not pregnant.
13 
However, studies of treatment in pregnancy so far have 
been largely done in southeast Asia.
14–16 PCR-adjusted 
ACT trials in Africa are scarce and have been limited 
mostly to non-ﬁ  xed-dose combinations.
17–20
Artemether–lumefantrine is a ﬁ  xed-dose combination 
that has proved safe and eﬀ  ective against infections with 
Plasmodium falciparum, including one study in pregnancy 
in Asia,
21 but there are no data from pregnant women in 
Africa. Our objective was to compare the eﬃ   cacy  of 
artemether–lumefantrine with that of quinine in the 
treatment of uncomplicated malaria in pregnancy in 
Lancet Infect Dis 2010; 
10: 762–69
Published Online
October 6, 2010
DOI:10.1016/S1473-
3099(10)70202-4
See Reﬂ  ection and Reaction 
page 739
Epicentre, Paris, France 
(P Piola MD, E A Ashley MD, 
P J Guerin MD); Epicentre, 
Mbarara, Uganda (P Piola, 
C Nabasumba MD, 
E Turyakira MSc, M Dhorda MS, 
D Nyehangane BMLS); Mbarara 
University of Science & 
Technology, Mbarara, Uganda 
(E Turyakira); Mahidol-Oxford 
Tropical Medicine Research 
Unit, Faculty of Tropical 
Medicine, Mahidol University, 
Bangkok, Thailand 
(N Lindegardh PhD, 
R McGready MD, 
Prof F Nosten MD); Centre for 
Clinical Vaccinology and 
Tropical Medicine, Nuﬃ   eld 
Department of Clinical 
Medicine, University of Oxford, 
Oxford, UK (P Piola, 
N Lindegardh, R McGready, 
Prof F Nosten, P J Guerin); 
INSERM UMR S945, Paris, 
France (G Snounou PhD); 
Université Pierre & Marie Curie, 
Faculté de Médecine Pitié-
Salpêtrière, Paris, France 
(G Snounou); Department of 
Microbiology, Imperial College 
NHS Trust, London, UK 
(E A Ashley); and Shoklo Malaria 
Research Unit, Mae Sot, Tak, 
Thailand (R McGready, 
Prof F Nosten)
Correspondence to:
Dr Patrice Piola, WWARN, Clinical 
Module, Centre for Tropical 
Medicine, CCVTM, University of 
Oxford, Churchill Hospital, 
Old Road, Oxford OX3 7LJ, UK
patrice.piola@wwarn.orgArticles
www.thelancet.com/infection   Vol 10   November 2010  763
Uganda. Secondary objectives included establishing the 
safety proﬁ  le of both treatments, comparison of fever and 
parasite clearance times, comparison of maternal, 
obstetric, and infant outcomes, and recording of 
lumefantrine blood concentrations at day 7.
Methods
Participants
Between October, 2006, and May, 2009, we did an open-
label, randomised, non-inferiority eﬃ     cacy trial at the 
antenatal clinics of the Mbarara University of Science 
and Technology Hospital in Uganda. 
Women with positive blood smears during weekly 
antenatal follow-up were invited to participate in the 
study comparing the eﬃ   cacy and tolerance of artemether–
lumefantrine with quinine hydrochloride for the 
treatment of uncomplicated falciparum malaria. Women 
were eligible if they had a viable pregnancy with an 
estimated gestation of 13 weeks or longer and had malaria 
infection detected by microscopy (P falciparum mixed or 
monoinfection). Women were excluded if they had 
P falciparum parasitaemia of greater than 250  000 para-
sites per μL, severe anaemia (haemoglobin <7 g/dL), 
signs or symptoms of severe or complicated malaria 
needing parenteral treatment, known allergy to the study 
drugs, previous participation in the eﬃ   cacy study, or an 
inability to attend follow-up. WHO inclusion criteria 
referring to fever or to a lower limit of parasitaemia were 
not used because they do not include the eﬀ  ect of low 
parasitaemia in pregnancy.
All patients provided written informed consent. Our 
study proposal was submitted and approved by four ethics 
committees: the Faculty Research Ethics Committee, the 
Institutional Review Board, the Uganda National 
Committee for Science and Technology, and the Comités 
de Protection des Personnes (Iles de France XI, France).
Procedures 
After inclusion, eligible patients were randomly assigned 
(1:1) to the two intervention groups in computer-generated 
permuted blocks of eight. Each inclusion number 
corresponded to an opaque sealed envelope that contained 
a card with the concealed treatment group. The sealed 
envelope was opened by a clinical investigator after 
patients’ consent had been obtained; the clinical 
investigator was not involved in the generation of the 
allocation sequence. The allocation sequence was 
generated with a computerised system by a member of 
the research team who was not involved in the 
management of patient data. The diﬀ  erent  dosing 
schedules meant that the patients and the clinical 
investigators were aware of treatment allocation. 
Treatment allocation was masked from the laboratory 
that read the blood smears.
Participants received either quinine hydrochloride 
(300 mg of the base per tablet) given orally under 
supervision at 10 mg base per kg bodyweight every 8 h 
for 7 days, or artemether–lumefantrine (ﬁ  xed-dose 
combination of 20 mg and 120 mg) given orally under 
supervision as four tablets at 0 h, 8 h, 24 h, 36 h, 48 h, and 
60 h for 3 days with 200 mL of milk at each dose. We 
repeated doses if patients vomited within 30 min of 
administration, and gave the opposite intervention once 
if the patient vomited within 30 min after a repeat dose 
(the patient was then only followed up for safety).
Patients were followed up weekly until delivery. 
Baseline data on day 0 included a medical examination 
(bodyweight, blood pressure, and temperature), 
laboratory tests (blood smear, full blood count, liver 
Quinine 
(n=152)
Artemether–lumefantrine 
(n=152)
Mean age (range) 22·6 years (17-38) 22·5 years (15-38)
Median gravidity (range) 2 (1–7) 2 (1–8)
Mean weight (IQR) 58 kg (10) 58 kg (10)
Mean gestational age (range) 22·3 weeks (9–38) 24·7 weeks (10–39)
Gestation estimated by ultrasound 59% 60%
Proportion with history of fever 44·1% 33·6%
Fever (>37·5°C) 20% 23%
Geometric mean Plasmodium falciparum 
density (IQR)
1995 parasites per μL (9771) 1418 parasites per μL (4727)
Gametocyte carriage 9·2% 6·6%
Median (mean) blood haemoglobin 10·9 g/dL (10·9) 10·9 g/dL (10·9)
Median lymphocytes 1·64×10
9/L 1·76×10
9/L
Median neutrophils 2·69×10
9/μL 2·66×10
9/μL
Median platelets 138×10
9/L 148×10
9/L
Sickle cell trait 0/92 3/102 (1·6%)
QTc in baseline 368 ms 364 ms
Table 1: Baseline characteristics
Figure 1: Trial proﬁ  le
  152 in quinine group   152 in artemether–lumefantrine group
  304 randomly assigned
       10 lost to follow-up
       17 other deviations
         6 lost to follow-up
         8 other deviations
1197 individuals screened
    868 without malaria
       25 refused consent
  125 assessable at day 42   138 assessable at day 42
          5 lost to follow-up
       18 other deviations
         2 lost to follow-up
      26 other deviations
  102 assessable at delivery   110 assessable at delivery
Primary endpointArticles
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and kidney function, urine analysis, sickle-cell 
electrophoresis, and PCR), 12-lead electrocardiogram 
(ECG; repeated on day 2), and an obstetric ultrasound. 
On a weekly basis, from day 0 to day 42 or delivery 
(whichever came last), we recorded medical history, 
medical and obstetric examination (bodyweight, 
fundal height, blood pressure, and temperature), 
blood smear, liver and kidney function (days 7, 14, and 
42), lumefantrine plasma concentrations (day 7), full 
blood count (days 14 and 42), and adverse events. 
Intermittent preventive treatment in pregnancy was 
interrupted during this period. At delivery, mother, 
cord, placenta, and neonate blood smears were 
examined for parasites. Women in our study were not 
treated with sulfadoxine–pyrimethamine intermittent 
preventive treatment.
Thick and thin blood smears were prepared and stained 
with Giemsa. 200 high-power ﬁ  elds were read on the 
thick smear before declaring a slide negative. Parasitaemia 
was calculated by counting parasites against 200 white 
blood cells (or 500 if nine parasites or fewer were counted 
against 200 white blood cells) and with an assumed white 
blood cell count of 8000 cells per μL. External quality 
control was done at Shoklo Malaria Research Unit 
(Mae Sot, Tak, Thailand) on all slides collected at 
inclusion, at follow-up visits when recurrent parasitaemia 
was detected, and on an additional random selection of 
5% of all slides collected for the study.  
Peripheral blood samples for PCR genotyping were 
collected on Whatman 3MM paper strips (Whatman, 
Kent, UK) at baseline and reappearance. DNA was 
puriﬁ  ed with commercial kits (Qiagen, Hilden, Germany). 
Diﬀ   erentiation of recrudescence from new infections 
was done on samples collected concurrently with a 
positive slide and was on the basis of three P falciparum 
polymorphic markers: GLURP, MSP1, and MSP2. 
Parasitaemia during follow-up was classed as 
recrudescence when the parasites in the pretreatment 
and post-treatment samples shared at least one allelic 
variant for each of the three markers, and as a reinfection 
if the allelic variants for any one of the three markers 
were diﬀ  erent for the pretreatment and post-treatment 
samples.
22 An indeterminate result was reported if 
ampliﬁ   cation of any one marker failed from either 
samples, except when the partial analysis was suﬃ   cient 
to class the episode as a reinfection. Internal quality 
control (ten sample pairs) and external quality control 
(ﬁ  ve sample pairs) was done.
On day 7, all patients from the artemether–lumefantrine 
group were sampled (2 mL) by venepuncture for 
lumefantrine concentration. Plasma was separated and 
stored at –30°C until it was analysed with a validated high-
performance liquid chromatography method.
23
The primary eﬃ   cacy endpoint was the proportion of 
patients with PCR-corrected adequate clinical and 
parasitological response (ACPR) at day 42—cure is 
deﬁ  ned as ACPR. The secondary eﬃ   cacy endpoint was 
PCR-uncorrected ACPR on day 42 or delivery (whichever 
came last) to account for placental sequestration of 
malaria parasites. Treatment success or failures were 
classiﬁ  ed according to WHO guidelines 2003.
24
Safety outcomes were adverse events as deﬁ  ned by the 
International Conference on Harmonisation Good Clinical 
Practice guidelines.
25 Safety outcome events documented 
during pregnancy were abnormal laboratory parameters 
(alanine aminotransferase, bilirubin, creatinine, and full 
blood count outside normal lab ranges); abnormal 
Fridericia corrected QT interval (QTc; >440 ms) on ECG; 
gestation at delivery including prematurity (<37 weeks); 
extreme prematurity (<28 weeks); congenital abnormalities; 
low birthweight (<2500 g); and perinatal, neonatal, and 
infant death. Gestational age was determined with 
ultrasound scan before 24 weeks of gestation and last 
menstrual period for later inclusions in the trial.
The independent data monitoring committee met twice 
during the trial and reviewed all serious adverse events. 
Statistical analysis
The non-inferiority margin for the diﬀ  erence in cure 
rates between the two treatments was δ=5%. The PCR-
adjusted cure rate of quinine on day 42 was the chosen 
reference and estimated at 98%. The resulting number of 
Day 42 Delivery (or day 42 if later)
Quinine Artemether–lumefantrine Quinine Artemether–lumefantrine
PCR corrected
Percentage eﬃ   cacy (range) 97·6% (93·1–99·5) 99·3 % (96·0–99·9) 96·1% (90·2–98·9) 98·2% (93·5–99·7)
n/N (122/125) (137/138) (98/102) (108/110)
Diﬀ  erence (LLCI) +1·7 (–0·9%) +2·1 (–1·7%)
Not PCR correction
Percentage eﬃ   cacy (range) 96·1% (91·0–98·7) 99·3 % (96·0–99·9) 83·8% (75·8–89·9) 87·8% (80·7–93·0)
n/N (122/127) (137/138) (98/117) (108/123)
Diﬀ  erence (LLCI) +3·2 (+0·1%) +4·0 (–3·4%)
LLCI=lower limit of the one-sided 95% CI. 
Table 2: Cure rates (modiﬁ  ed intention to treat) by day 42 and delivery in women with uncomplicated Plasmodium falciparum malaria treated with 
quinine or artemether–lumefantrineArticles
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patients needed in each treatment group was 152, to 
allow for a type 1 error (α) of 5%, a power of 80%, and a 
proportion of dropout of 10%.
The non-inferiority analysis used the proportion of 
ACPR. We analysed estimates of recrudescence and 
reinfection rates with Kaplan-Meier methods. Data were 
analysed for  randomised patients except for those with 
protocol deviations that might aﬀ   ect the eﬃ   cacy 
outcome;
26 this adaptation of the intention-to-treat study 
population was made to account for the non-inferiority 
design. Participants who deviated from the protocol were 
excluded from the non-inferiority analysis (and censored 
on the day of last available parasitaemia in the survival 
analysis). We also did a per-protocol analysis.
We compared continuous data between the groups with 
the Student’s t test. Data not normally distributed were 
log transformed or compared by use of the Mann-Whitney 
U test χ². Comparison of categorical data between groups 
was done with the χ² test or with Fisher’s exact test.
We double-entered data into Epidata software 3.1 and 
analysed them with Stata (version 11). An independent 
data and safety monitoring board convened to review 
eﬃ     cacy and safety data at yearly intervals as the trial 
progressed. This study was registered with ClinicalTrials.
gov, number NCT00495508.
Role of the funding source
Médecins Sans Frontières and the European Commission 
funded the project but had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ  nal responsibility for the 
decision to submit for publication.
Results 
304 patients were enrolled and 152 assigned to each 
treatment group (ﬁ   gure 1). The webappendix shows 
details of deviations from the protocol that led to 
exclusion from the analysis. Baseline characteristics 
were similar in the two groups (table 1), most participants 
had anaemia (haemoglobin <11 g/dL) at enrolment and a 
ﬁ  fth were febrile. 
Seven participants did not ﬁ  nish their treatment or 
withdrew consent before the end of treatment (six in the 
quinine group and one in the artemether–lumefantrine 
group). Of those that interrupted treatment in the quinine 
group, three withdrew consent after 1 day of treatment 
and never returned, two refused to take the treatment 
and received a rescue treatment, and one delivered and 
discontinued treatment. 
Of the 29 patients who had recurrent falciparum 
parasitaemia between day 7 and delivery (or day 42 
whichever was last), PCR genotyping conﬁ  rmed that 22 
(76%; 12 on quinine and 10 on artemether–lumefantrine) 
were new infections, three (10% ; two on quinine on day 
14 and 138 and one on artemether–lumefantrine on 
day 119) were recrudescent, and four (14%; three on 
quinine and one on artemether–lumefantrine) were 
indeterminate. The median time to ﬁ  rst  P falciparum 
reappearance was 65 days (range 34–138) for quinine and 
70 (49–154) for artemether–lumefantrine (p=0·4).
Of the 13 patients with recurrent non-falciparum 
infections (six Plasmodium vivax, six Plasmodium ovale, 
and one Plasmodium malariae) by delivery (or day 42 
whichever was last), seven were on artemether–
lumefantrine and six were on quinine. The median time 
to ﬁ   rst non-falciparum detection was 63 days 
(range 35–133) in the artemether–lumefantrine group 
and 38 (28–70) in the quinine group (p=0·1).
Cure rates were high and the lower limit of the one-sided 
95% CI was never lower than –5% (table 2). The PCR-
uncorrected results also seemed to show non-inferiority 
(table 2), and the per-protocol analysis concluded the non-
Figure 2: PCR-adjusted and unadjusted survival curve
Number at risk
Artemether–
lumefantrine 152  149  145  142  137  57  17  1 
Quinine 152  145  140  132  124  66  17  1  
Number at risk
Artemether–
lumefantrine 152  150  146  143  138  59  17  1 
Quinine 152  145  140  132  124  66  17  1  
P
r
o
p
o
r
t
i
o
n
 
o
f
 
r
e
c
u
r
r
e
n
c
e
 
o
r
 
r
e
c
r
u
d
e
s
c
e
n
c
e
 
(
%
)
100
95
90
85
80
75
150 100 42 28 200
Follow-up (days)
B
14 7
P
r
o
p
o
r
t
i
o
n
 
o
f
 
r
e
c
u
r
r
e
n
c
e
 
o
r
 
r
e
c
r
u
d
e
s
c
e
n
c
e
 
(
%
)
100
95
90
85
80
75
A
See Online for webappendixArticles
766  www.thelancet.com/infection   Vol 10   November 2010
inferiority of artemether–lumefantrine (data not shown). 
No signiﬁ  cant diﬀ  erence between the two treatments was 
noted with Kaplan-Meier analysis of recurrence or 
recrudescence (ﬁ  gure 2).
Fever clearance was rapid in both groups (table 3). On 
day 2, parasite clearance was lower in the quinine group 
than in the artemether–lumefantrine group (p<0·0001; 
table 3) but increased on day 3. Artemether–lumefantrine 
was more eﬀ  ective than quinine in gametocyte clearance 
by day 2 (p=0·03) and day 7 (p=0·04; table 3). Four 
women without gametocytes at inclusion had gametocytes 
on day 7 (three taking quinine and one taking artemether–
lumefantrine), and one on day 42 (quinine).
Placenta blood smears were obtained for 214 (76%) of 
281 births. Ten smears (4·7%), ﬁ  ve per group, were positive 
for P falciparum (ﬁ  gure 3). In six cases, both mother and 
placenta were positive: ﬁ  ve were still under initial treatment 
(three on quinine and two on artemether–lumefantrine) 
and one (artemether–lumefantrine) with a new infection at 
the time of delivery. Of the four women with a negative 
peripheral blood smear, three had their primary treatments 
(two had quinine and one had artemether–lumefantrine) 
132, 118, and 8 days before delivery. The fourth woman was 
in the quinine group and was treated with artemether–
lumefantrine 182 days before delivery and she had a new 
infection 63 days later—ie, 119 days before delivery (ﬁ  gure 3). 
235 (87%) of 281 newborns were screened for malaria within 
24 h of birth, none of whom were positive for malaria.
There was a gain in haemoglobin of 0·8 g/dL in both 
groups 42 days after treatment, after an initial mean 
decrease at day 7 in the artemether–lumefantrine group: 
decrease of 0·5 g/dL in artemether–lumefantrine vs gain 
of 0·3 g/dL in quinine (p<0·0001; ﬁ  gure 4).
At delivery, mean haemoglobin was 12·1 g/dL 
(range 7·4–16·8) in the quinine group compared with 
11·9 g/dL (8·0–15·7) in the artemether–lumefantrine 
group (p=0·45). Of the women from whom we could 
obtain blood at the moment of delivery, three (3%) of 107 
had severe anaemia in the quinine group and one (1%) of 
122 in the artemether–lumefantrine group (p=0·24).
Laboratory tests did not show any clinically signiﬁ  cant 
adverse event. 14 days after treatment there was no 
neutropenia recorded in either group. We noted four cases 
of lymphopenia in the artemether–lumefantrine group 
(one reached 0·75×10
9 cells per L) and none in the quinine 
group. In both groups, by day 42, platelets increased by 
about 50% and eosinophils doubled (11 adverse events in 
the quinine group and ﬁ  ve in the artemether–lumefantrine 
group). No substantial diﬀ   erence in alanine amino-
transferase, bilirubin, creatinine, and full blood count 
were noted between the groups. 
Of the women that did not have a prolonged QTc at 
inclusion, two (1%) of 149 developed a prolonged QTc at 
day 2 in the quinine group (highest QTc 530 ms) and 
three (2%) of 151 in the artemether–lumefantrine group 
(highest QTc 590 ms; p=0·66).
The most common symptoms reported before 
treatment were headache, abdominal pain, dizziness, 
and weakness (table 4). In the quinine group 142 (93%) of 
152 patients presented at least one adverse event 
compared with 94 (61·8%) in the artemether–
lumefantrine group (p<0·0001). The most common 
adverse event after treatment was tinnitus, noted only in 
the quinine group after a median of 2 days, and it resolved 
in 94 (85%) of 111 women within a week of completing 
treatment. Other common adverse events in the quinine 
group after treatment were nausea (peaking at a median 
2 days), vomiting (3 days), and anorexia (3 days). 
Inﬂ   uenza-like syndrome and headache were also 
Quinine Artemether–lumefantrine
Afebrile at day 0 121/151 (80%) 117/152 (77%)
Afebrile at day 1 128/129 (99%) 127/132 (96%)
Afebrile at day 2 127/128 (99%) 130/130 (100%)
Afebrile at day 3 146/146 (100%) 149/149 (100%)
Gametocyte free at day 2 133/143 (93%) 147/149 (99%)
Gametocyte free at day 7 135/143 (94%) 142/143 (99%)
Parasite free at day 2 123/143 (86%) 148/149 (99%)
Parasite free at day 3 141/144 (98%) 136/137 (99%)
Data are number/total number (%).
Table 3: Fever and parasite clearance Figure 3: Results of placental blood smears
  3 positive peripheral 
      blood smears 
      (2 under treatment 
      and 1 reinfection)
  5 in the artemether–lumefantrine group
  2 negative peripheral 
      blood smears 
      (treated 8 days and 
      132 days before 
      delivery)
  3 positive peripheral 
      blood smears 
      (all under treatment)
  2 negative peripheral 
      blood smears 
      (treated 118 days 
      and 119 days before 
      delivery)
  5 in the quinine group
10 positive placental blood smears at delivery
Figure 4: Variation of haemoglobin
–10
Artemether–
lumefantrine
Quinine
–5 0 5
Variation of haemoglobin (g/dL)
Day 0–7
Day 0–14
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common, happening between a median delay of 21 days 
and 14 days after start of treatment and not substantially 
diﬀ  erent between groups. Common adverse events in 
the artemether–lumefantrine group were abdominal 
pain (5 days), headaches (4 days), and inﬂ  uenza-like 
syndrome (21 days).
The one serious adverse event was a maternal death in 
a woman in the quinine group with her ﬁ  rst pregnancy. 
Death was caused by sepsis 5 days after a caesarean 
section for obstructed labour in a term pregnancy. 
Birth outcomes were documented in 137 (90%) 
of 152 women in the quinine group and in 144 (95%) 
of 152 in the artemether–lumefantrine group. There were 
a few spontaneous abortions and neonatal deaths, 
all proportionally lower (non-signiﬁ   cant) in the 
artemether–lumefantrine than in the quinine group 
(table 5).
Malformations detected at birth included two neonates 
with polydactyly in each group, which was a family trait 
in both, and one with acyanotic heart disease in a woman 
treated with artemether–lumefantrine at 19 weeks 
of gestation. 
181 (65%) of 280 women on whom we could obtain the 
date of delivery, had their gestational age deﬁ  ned  by 
ultrasound, the remainder being included after 24 weeks 
of pregnancy. No signiﬁ  cant diﬀ  erence in mean birth-
weight, proportion of low birthweight, mean gestational 
age, or premature or severely premature infants was 
noted (table 6). 
Of the 152 women in the artemether–lumefantrine 
group, plasma lumefantrine concentrations at day 7 were 
available for 97 women (64%) who had completed their 
treatment (median 481 ng/mL; range 15–3246). 31 (32%) 
of 97 had a lumefantrine concentration of less than 
280 ng/mL. In six women, the reappearance of malaria 
(two non-falciparum, one recrudescence, two new 
falciparum, and one indeterminate) was associated with 
signiﬁ  cantly lower lumefantrine concentrations than in 
the 91 with no reappearance (240 ng/mL [123–454] vs 
422 ng/mL [15–3246]; p=0·01). Five of the six women 
with recurrent parasitaemia had lumefantrine 
concentrations of less than 280 ng/mL.
Discussion
Our ﬁ  ndings show that artemether–lumefantrine eﬃ   cacy 
was non-inferior to quinine for the treatment of 
uncomplicated malaria in the second and third trimesters 
of pregnancy. This conﬁ  rmation of eﬃ   cacy of both drugs 
in this region of Africa is reassuring. Most pregnant 
women included in this study were asymptomatic with low 
parasitaemia, which is suﬃ   cient to complicate a pregnancy 
and fetal growth.
27 The poor tolerability of quinine caused 
patients to interrupt treatment (data not shown).
Placental infection at delivery in all women in Africa 
has been estimated at 26% (range 5–52%).
1 In our study, 
in which all women had slide-conﬁ  rmed malaria, eﬀ  ective 
treatment during pregnancy, and active weekly detection, 
only four (2%) of 214 women that ﬁ  nished their treatment 
had an apparent microscopic infection at delivery. This 
rate is similar to ﬁ  ndings from the low-transmission site 
in Thailand.
21 Our study suggests that active detection 
and treatment by weekly malaria smear substantially 
decreases the risk of patients having parasites in the 
peripheral and placental blood at the time of delivery. 
Active antenatal screening rather than passive case 
management should be encouraged in all areas where 
malaria is endemic. 
In southeast Asia,
21 PCR conﬁ  rmed  eﬃ   cacy  of 
artemether–lumefantrine (intention to treat) in pregnant 
women was lower (82·0%; range 74·8–89·3) at delivery 
(or day 42 if later) than in our study (98·2%; 93·5–99·7%). 
Several factors might explain this diﬀ  erence: in Thailand, 
Quinine Artemether–lumefantrine p*
Baseline 
symptom
Adverse 
event 
Median 
delay (days)
Baseline 
symptom 
Adverse 
event 
Median 
delay (days) 
Tinnitus 0 111  (73%) 2 0 0 0 <0·0001
Abdominal pain  35 (23%) 46 (30%) 3 24 (16%) 43 (28%) 5 0·8010
Inﬂ  uenza-like 
syndrome 
5 (3%) 18 (12%) 21 10 (7%) 25 (16%) 21 0·3234
Weakness  13 (9%) 23 (15%) 2 12 (8%) 13 (9%) 5 0·1101
Headache  71 (47%) 9 (6%) 14 57 (38%) 26 (17%) 4 0·0040
Nausea  5 (3%) 26 (17%) 2 5 (3%) 8 (5%) 2.5 0·0020
Vomiting  5 (3%) 28 (18%) 3 3 (2%) 6 (4%) 18.5 0·0001
Dizziness  14 (9%) 13 (9%) 2 15 (10%) 14 (9%) 3 1
Anorexia  2 (1%) 16 (11%) 3 2 (1%) 6 (4%) 9 0·0463
*p value testing the diﬀ  erence in proportion of adverse events.
Table 4: Adverse events 
Deliveries or births Quinine (n=137) Artemether–lumefantrine (n=144)
Spontaneous abortions (<20 weeks) 2 (1·5%) 2 (1·4%)
Intrauterine fetal deaths (>20 weeks) 2 (1·5%) 1 (0·7%)
Stillbirths  3 (2·2%) 2 (1·4%)
Early neonatal deaths (before week 1 after birth) 6 (4·4%) 3 (2·1%)
Data are number (%).
Table 5: Spontaneous abortions and perinatal deaths
Quinine Artemether–lumefantrine
Gestational age at delivery
Number assessed 137 143
Mean gestational age (weeks) 39·2 (95% CI 38·6–39·9) 39·6 (95% CI 39·2–40·1)
Prematurity (<37 weeks) 17 (12·4%) 12 (8·4%) 
Severe prematurity (<28 weeks) 4 (2·9%) 2 (1·4%)
Birthweight
Number assessed 119 120
Mean birthweight (g) 3012 (95% CI 2074–3950) 3045 (95% CI 2165–3925)
Low birthweight (<2500 g) 16 (13·4%) 12 (10·2%)
Term low birthweight (<2500 g) 5/106 (4·7%) 10/112 (8·9%)
Table 6: Gestational age and birthweight at delivery Articles
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less than 60% of pregnant women are cured when 
treated with 7 days supervised quinine,
15 probably related 
to the high background prevalence of pfmdr1 in the 
population.
28 In a mesoendemic area like Mbarara, 
pregnant women have a higher level of background 
immunity suggested by the lower proportion of women 
with febrile presentation and lower baseline parasitaemia 
(about three-times lower) than in the Thailand study. 
The longer parasite reappearance time in this study 
compared with that in the Thailand study might also be 
explained by a diﬀ  erence in immunity. Drug absorption 
could also have a role, as shown in our study by the 
higher risk of recurrent parasitaemia in women with 
lower concentrations of blood lumefantrine at day 7. 
However, a third of women without recurrent 
parasitaemia had lumefantrine concentrations on day 7 
lower than 280 ng/mL, suggesting that drug 
concentrations alone might not explain the diﬀ  erence in 
eﬃ     cacy between sites. Although non-falciparum 
infections are not widely reported from Africa, 30% of 
the reappearances in our study were non-falciparum 
infections. The prophylactic eﬀ  ect of antimalarials in 
pregnancy is important, as even a single P vivax parasite 
has been associated with low birthweight and anaemia.
29 
Another factor that could contribute to a diﬀ  erence in 
results is the method of analysis,
30 mainly the allocation 
of eﬃ   cacy endpoints to diﬀ  erent deviations.
Although, our study was done at a single site, the 
results should be interpreted in the epidemiological 
context of the study site. Scaling up of ACTs in pregnancy 
will need further assessment of their eﬃ   cacy and safety 
in other regions. We used sealed envelopes because it 
suited our setting, although central mechanisms ensure 
better randomisation.
Our study also provides supportive safety data for the 
use of artemisinin derivatives in pregnant women. The 
rise in platelets over time can be interpreted as a sign of 
recovery from malaria and is known to cause 
thrombocytopenia.
31 The transitory fall in haemoglobin, 
mostly in the artemether–lumefantrine group, might be 
related to a haematological eﬀ  ect of artemisinins
32 or 
directly related to the pathophysiology of malaria 
infection. Early Chinese studies of artemether and oral 
dihydroartemisinin treatments
33 recorded low reticulocyte 
counts in 10–20% of patients during the ﬁ  rst week after 
treatment. More women in the quinine group and in the 
artemether–lumefantrine group had severe anaemia at 
delivery, but the study was not powered to detect a 
signiﬁ  cant diﬀ  erence for this comparison. However, the 
sample size of our study was not calculated for the 
detection of rare adverse events.
The day 7 lumefantrine plasma concentration is deemed 
to be the main determinant of eﬃ   cacy in non-pregnant 
patients, and concentrations below 280 ng/mL is the 
threshold associated with increased risk of treatment 
failure.
34 A similar proportion of women in the Thailand 
study (35%) and in our Uganda study (32%) had day 7 
plasma lumefantrine concentrations below this threshold. 
The kinetics of lumefantrine are altered in pregnancy, 
and in our trial women with recurrent infections had 
lower than expected lumefantrine concentrations. Our 
ﬁ  ndings conﬁ  rm those in Thailand and the importance of 
pharmacokinetic and pharmacodynamic studies in trials 
of malaria treatment.
35 Although cure rates were adequate, 
the substantial proportion of pregnant women with 
lumefantrine concentrations below the threshold might 
have serious ramiﬁ   cations on the development of 
resistance: wide deployment of artemether–lumefantrine 
in Africa might result in high numbers of women 
receiving subtherapeutic concentrations, which increase 
the chance of failure for the individual patient and 
potentially threaten the long-term therapeutic life of the 
drug. Sulfadoxine-pyrimethamine and meﬂ  oquine both 
have a history of subtherapeutic doses and the subsequent 
loss of the drug as monotherapy.
36 More detailed 
pharmacokinetic data is being assessed.
Prices of ACTs, and in particular artemether–lumefan-
trine, have dropped substantially in recent years and 
therefore make treatment costs comparable to those for 
quinine. Additionally, large funding agencies such as the 
Global Fund to Fight AIDS, Tuberculosis and Malaria or 
the President’s Malaria Initiative are now largely 
subsidising ACTs. This improves the cost-eﬀ  ectiveness of 
ACTs compared with that of quinine. 
Our study suggests that artemisinin derivatives, 
depending on the companion drug, could be preferable to 
oral quinine for the treatment of uncomplicated malaria in 
pregnancy, because they are better tolerated with reassuring 
safety results and not inferior to quinine in eﬃ   cacy. 
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